Research & Development (R&D) efforts in large pharmaceutical companies has been significantly reduced in order to accommodate late stage mergers and acquisitions. This has created opportunity for IPAC to fill the gap in R&D, allowing us to create robust product pipelines and bring more innovative treatments to patients in China/Asia.
A core problem in the eye care industry is not only the ability to develop a promising drug, but the inability to deliver those drugs to the necessary ocular tissue in effective doses. Drug delivery technologies that have advanced in other fields of medicine have failed to fully penetrate ophthalmology pharmaceutical products…. Until now. New technologies, including nano-encapsulation, are providing a breakthrough in the ability to deliver drugs to the eye.
Through various licensing agreements, we have access to these ground-breaking technologies that we will use to enhance optical treatments.